SCHEMBL4159966

SCHEMBL4159966

CCNS(=O)(=O)c1cccc(NC(=N)N)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
MAPT P10636 2/20 0.49
ALOX15 P16050 2/20 0.49
MAPK1 P28482 2/20 0.49
TSHR P16473 1/20 0.49
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
TP53 P04637 1/20 0.48
HTT P42858 1/20 0.48
CA1 P00915 7/20 0.47
CA2 P00918 7/20 0.47
ALDH1A1 P00352 3/20 0.47
CA12 O43570 3/20 0.46
CA9 Q16790 3/20 0.46
F2 P00734 3/20 0.45
TMPRSS6 Q8IU80 2/20 0.45
TNNI3K Q59H18 1/20 0.45
KIT P10721 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4162355 0.84 CYP2C19 (0.55) MAPTKMT2AMEN1CA1CA2
SCHEMBL4151992 0.84 LMNA (0.52) LMNAMAPTKMT2AMEN1CA1
SCHEMBL4165927 0.83 ALDH1A1 (0.50) LMNAMAPTALOX15MAPK1TSHR
SCHEMBL4173576 0.82 NAMPT (0.61) LMNAMAPTMAPK1HTTCA1
SCHEMBL4158719 0.82 LMNA (0.58) LMNAMAPTALOX15MAPK1TSHR
SCHEMBL18175934 0.80 TNNI3K (0.49) LMNAMAPTALOX15MAPK1TSHR
SCHEMBL1592707 0.80 LMNA (0.53) LMNAMAPTKMT2AMEN1CA1
SCHEMBL4163332 0.80 LMNA (0.51) LMNACA1CA2CA12CA9
SCHEMBL4163423 0.80 PKM (0.50) LMNAMAPTTSHRCA1CA2
SCHEMBL4158733 0.79 KIF18A (0.49) LMNAMAPTKMT2AMEN1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CYCLACEL LIMITED (GB) 2009-05-28 US disclosed
EP-1756098-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cyclacel Limited (GB) 2007-02-28 EP disclosed
WO-2005116025-A2 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CYCLACEL LIMITED (GB) 2005-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137572-A1 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders CDK2, CDK4, CDK20 LMNA 1768/4885MAPT 2054/4885ALOX15 3465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.